FDA Advisory Committee Recommends Adding BPC-157 to Compounding List
A closely watched FDA advisory committee has voted to recommend adding BPC-157 to the list of bulk drug substances that may be used by traditional compounding pharmacies, marking a potentially significant development for providers who have followed growing interest in peptide therapies.
On July 23, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) voted to recommend adding BPC-157 to the list of bulk drug substances that may be used by state-licensed compounding pharmacies under Section 503A of the Federal Food, Drug, and Cosmetic Act. The recommendation follows extensive discussion regarding the peptide’s safety, effectiveness and potential clinical need. The committee evaluated BPC-157 (free base) and BPC-157 acetate for use in ulcerative colitis.
The vote does not mean BPC-157 has been approved by the FDA, nor does it immediately change federal compounding rules. The committee’s recommendation is advisory, and the FDA will now review the recommendation, public comments and the administrative record before determining whether to move forward with rulemaking.
The PCAC is considering these seven peptide substances in a meeting July 23-24: BPC-157, KPV, TB-500, MOTS-C, Semax, Epitalon, Emideltide.
What the Vote Means
Traditional 503A compounding pharmacies generally may not compound medications from bulk drug substances unless those ingredients meet specific statutory requirements, including inclusion on the FDA’s 503A Bulks List.
The Pharmacy Compounding Advisory Committee reviews scientific evidence, safety information and clinical need before making recommendations to the FDA regarding whether a substance should be included on that list.
BPC-157 (free base)/BPC-157 acetate was evaluated for use in ulcerative colitis (UC).
During the July meeting, FDA reviewers raised concerns about the limited human clinical evidence supporting BPC-157’s safety and effectiveness. Committee members nevertheless voted to recommend inclusion after considering available data as well as testimony from physicians, compounders and patients who argued that the peptide fulfills an unmet clinical need.
The FDA is not required to follow the committee’s recommendation, but PCAC votes often play an important role in the agency’s decision-making process.
What Happens Next?
The FDA will determine whether to issue a proposed rule that would add BPC-157 to the 503A Bulks List. If the agency moves forward, additional regulatory steps and public comment opportunities would likely occur before any change becomes final.
Even if BPC-157 is ultimately added to the list, it would remain an unapproved drug. Inclusion on the 503A Bulks List would simply permit qualified compounding pharmacies to compound preparations containing BPC-157 when all applicable federal and state requirements are met, including the requirement for valid patient-specific prescriptions.
Medical spas should also remember that state laws governing prescribing authority, delegation, supervision and administration of compounded medications would continue to apply.
What Is BPC-157?
BPC-157, short for Body Protection Compound-157, is a synthetic peptide consisting of 15 amino acids. It is derived from a protein fragment originally identified in human gastric juice and has attracted attention because of research suggesting potential effects on tissue repair and healing.
Researchers have studied BPC-157 in laboratory and animal models involving tendon injuries, ligament healing, gastrointestinal disorders and other conditions. Proposed mechanisms include promoting blood vessel formation, influencing inflammatory pathways and supporting tissue repair processes.
Despite widespread interest, human research remains limited. Researchers emphasize the need for larger, well-designed clinical trials to establish safety and effectiveness.
Why Has BPC-157 Become So Popular?
Interest in peptide therapies has expanded rapidly in recent years, fueled by social media, longevity medicine, functional medicine and sports recovery communities.
Patients frequently seek information about BPC-157 for claims involving injury recovery, joint and tendon health, post-surgical healing and gastrointestinal support. However, many of these claims are based primarily on anecdotal reports and preclinical research rather than large human clinical trials.
Because BPC-157 has never been approved by the FDA, it cannot legally be marketed as an approved treatment for these conditions.
BPC-157 Use in Athletes
BPC-157 is a hot topic in sports medicine and athletic recovery discussions, thanks to its reported influence in tissue and ligament healing.
However, this peptide has been on the World Anti-Doping Agency (WADA) prohibited list under Class S0 (Non-Approved Substances) since 2022. It is prohibited at all times in an out of competition and is not eligible for the therapeutic use exemption because it has no approved therapeutic uses. Athletes governed by WADA could face disqualification is they have BPC-157 in their systems.
BPC-157 Peptide Stacks
Peptide stacking = administration of multiple peptide substances to combine their effects.
Some influencers promote peptide “stacks” that combine BPC-157 with TB-500 to support connective tissue recovery. TB-500 is a synthetic heptapeptide version of thymosin beta-4, and in animal studies has influenced cellular mobility and structural remodeling during wound healing and tissue regeneration. The pairing aims to doubly tackle wound healing.
TB-500 is being evaluated for wound healing by PCAC.
Some stackers combine BPC-157 with CJC-1295/ipamorelin for athletic recovery. Ipamorelin is a synthetic pentapeptide (five amino acid chain) that stimulates growth hormone release by binding to the ghrelin receptor in the brain. CJC-1295 is a modified peptide that mimics growth-hormone-releasing-hormone to secrete growth hormone that doesn’t broken down as quickly as synthetic GH. Ipamorelin and CJC-1295 are commonly paired to produce a stronger growth hormone pulse, to aid in body composition, soft-tissue repair and sleep quality.
What Does the Science Say?
Animal and laboratory studies have produced promising findings related to tissue repair, tendon healing, ligament recovery and gastrointestinal protection. However, published human data remain sparse, and there are currently no large randomized clinical trials demonstrating safety and effectiveness for any approved indication.
That evidence gap was a central issue during the FDA advisory committee’s deliberations.
FDA reviewers questioned whether existing clinical data sufficiently establish BPC-157’s safety profile or demonstrate meaningful clinical benefit. Supporters argued that the peptide has been used in practice for years and warrants broader access and additional study.
Considerations for Medical Spas
Patient interest in peptide therapies is unlikely to disappear regardless of the FDA’s final decision. As questions about BPC-157 continue, medical spas should focus on compliance, patient education and evidence-based communication.
If the FDA eventually adds the peptide to the 503A Bulks List, practices considering offering compounded BPC-157 should carefully evaluate:
- State laws governing prescribing and administration;
- Physician oversight requirements;
- Relationships with licensed compounding pharmacies;
- Appropriate patient selection;
- Informed consent procedures;
- Documentation and medical necessity;
- Advertising and marketing claims.
Providers should also avoid overstating the available evidence. While patients may encounter bold claims online regarding accelerated recovery, anti-aging effects or enhanced performance, those claims have not been established through robust clinical research.
The Bottom Line
The FDA must still decide whether to adopt the Pharmacy Compounding Advisory Committee’s recommendation to add BPC-157 to the 503A Bulks List. If that occurs, qualified compounding pharmacies may be able to compound BPC-157 under specific legal conditions, but the peptide would remain an unapproved drug and would not become FDA-approved therapy.
For medical spa professionals, the committee vote represents an important regulatory development, but not the final chapter. The FDA’s decision will ultimately determine whether BPC-157 gains a pathway for traditional compounding, and providers should continue monitoring the agency’s next steps while maintaining an evidence-based approach to patient care.
Still on the docket for July 23 KPV, TB-500 and MOTs-C. July 24: Emideltide, Semax and Epitalon. Stay tuned for updates.
